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Abstract
Lipid peroxidation is elevated in diseased regions of brain in several neurodegenerative diseases. Acrolein (2-propenal) is a
major cytotoxic product of lipid peroxidation and its adduction to neuronal proteins has been demonstrated in diseased brain
regions from patients with Alzheimer’s disease. Mitochondrial abnormalities are implicated in several neurodegenerative
disorders, and mitochondria are targets of alkenal adduction in vivo. We examined the effects of acrolein upon multiple
endpoints associated with the mitochondrial involvement in neurodegenerative disease. Acrolein inhibited state 3 respiration
with an IC50 of approx. 0.4 Wmol/mg protein; however, there was no reduction in activity of complexes I^V. This inhibition
was prevented by glutathione and N-acetylcysteine. Acrolein did not alter mitochondrial calcium transporter activity or
induce cytochrome c release. These studies indicate that acrolein is a potent inhibitor of brain mitochondrial
respiration. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lipid peroxidation, resulting from free radical
damage to polyunsaturated fatty acids, occurs in
Alzheimer’s disease, Parkinson’s disease, and in acute
cerebral cell death following ischemia [1^4]. Lipid
peroxidation generates cytotoxic alkenals such as
4-hydroxynonenal (HNE) and 2-propenal, commonly
known as acrolein. These alkenals exert cytotoxicity
by adducting cellular nucleophilic groups found on
proteins, nucleic acids, or aminophospholipids [5^8].
The levels of unreacted HNE and HNE-protein ad-
ducts as well as acrolein-protein adducts are elevated
in diseased regions of brain from patients with Alz-
heimer’s disease and Parkinson’s disease [3,9^13].
Acrolein formation from arachidonic acid in vitro
has been reported to be approx. 40-fold greater
than that of HNE [14]. Given that acrolein is esti-
mated to be approx. 100-fold more reactive than
HNE towards nucleophiles, acrolein may be of par-
ticular importance in neurodegenerative disease
[7,15].
Mitochondria are implicated in several neurode-
generative disorders and are targets of alkenal ad-
duction in vivo [16^19]. Mitochondria are a site of
free radical generation, and mitochondrial mem-
branes contain signi¢cant amounts of arachidonic
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and linoleic acids, precursors of HNE and acrolein
[20^22]. Mitochondria oxidized in vitro form HNE-
protein adducts, and cardiac mitochondria isolated
from rodent hearts following ischemia-reperfusion
injury contain HNE-protein adducts [18,23]. Follow-
ing cerebral ischemia in rodents, HNE-protein ad-
duct immunoreactivity co-localized with that of
Bcl-2, suggesting the presence of HNE adducts on
central nervous system (CNS) mitochondrial proteins
[19].
Because of the relevance of lipid peroxidation
products and mitochondria to neurodegeneration,
we studied whether acrolein modi¢ed the physiology
of mitochondria isolated from brain by examining
several mitochondrial endpoints associated with neu-
rodegenerative disease. Our data show that acrolein
primarily inhibits mitochondrial respiration at sev-
eral levels but does not compromise complexes I^V.
Cytochrome c release and calcium transporter func-
tion were not altered by acrolein exposure.
2. Materials and methods
2.1. Reagents
Acrolein (Aldrich) was freshly distilled the day of
use. HNE was synthesized according to methods
used in this laboratory [5]. Propionaldehyde, gluta-
thione (reduced form), and N-acetylcysteine were
purchased from Sigma. Ruthenium(III) chloride ox-
ide (ruthenium red) was purchased from Alfa Aesar
Chemicals.
2.2. Isolation of mitochondria
Whole brain mitochondria (synaptic and non-syn-
aptic) were isolated from adult, male, Sprague-Daw-
ley rats (Harlan) based on the procedure of Rosen-
thal et al. [24]. Isolation bu¡er consisted of mannitol
(0.21 M), sucrose (70 mM), HEPES (5 mM), ethyl-
ene glycol-bis(L-aminoethyl ether)-N,N,NP,NP-tetra-
acetic acid (EGTA; 1 mM), and bovine serum albu-
min (BSA; 1 mg/ml) with a ¢nal pH of 7.4 at 4‡C.
Rat were deeply anesthetized with ketamine (100
mg/ml, i.p.) and xylazine (13 mg/ml, i.p.) [25]. The
brains were removed and homogenized in 10 ml per
brain of ice cold bu¡er. The homogenates were then
further diluted to 40 ml per brain and centrifuged at
3000Ug for 2 min (4‡C) to pellet nuclei and cellular
debris. The supernatant was then centrifuged at
12 000Ug (4‡C) for 10 min. The pellet was resus-
pended in 10 ml of homogenization bu¡er and 20 Wl
of 10% digitonin was added to disrupt the synapto-
somes. The suspension was then centrifuged as
above. The pellet was resuspended in bu¡er (10 ml)
without BSA or EGTA and centrifuged. This ¢nal
pellet was resuspended in 0.5 ml of bu¡er without
BSA or EGTA. Typically, the brain of one animal
was used per preparation per day. Protein concen-
tration was measured using Protein Assay Reagent
(Bio-Rad) with BSA as the standard.
2.3. Respiratory measurements
Respiration was measured using an oxygen elec-
trode (YSI International) and oxygen consumption
chamber (Gilson Medical Electronics). Experiments
were performed at 37‡C. Assay medium contained
125 mM KCl, 5 mM MgCl2, 2 mM KPO4 and
5 mM HEPES-KOH (pH 7.4). Mitochondria were
diluted to 0.1 mg/ml. Complex I-linked substrates
(5 mM glutamate and malate) or complex II-linked
substrate (5 mM succinate with 1 Wg/ml rotenone)
were used. State 3 respiration was measured for
2 min following ADP (1 mM) addition [25]. Speci¢c
experimental protocols are given in the ¢gure
legends.
2.4. NADH oxidase:cytochrome c reductase
measurement
Electron transport function from complex I to
complex III was analyzed by determining NADH
oxidase:cytochrome c reductase activity in a micro-
well format [26]. Mitochondria (0.1 mg/ml ¢nal con-
centration) were incubated in the respiratory medium
(1.2 ml) for 5 min with acrolein, pelleted by centri-
fugation (14 000Ug for 5 min), resuspended in 0.3 ml
of oxidase assay bu¡er (25 mM potassium phos-
phate, pH 7.4, with 5 mM MgCl2), and frozen at
380‡C. Assays were performed at 37‡C. Freeze-
thawed mitochondria (40 Wg of protein) were added
to assay bu¡er (0.16 ml) containing oxidized cyto-
chrome c (50 WM; Sigma) and 0.5 mM KCN and
incubated for 5 min. NADH (0.24 mM, 10 Wl) was
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added to start the reaction and the increase in absor-
bance at 548 nm measured using an adjustable wave-
length plate reader (SpectraMax). Rotenone (1 Wg/ml)
and antimycin A (1 Wg/ml) were added to determine
the nonenzymatic rate of reduction that was sub-
tracted from all samples.
2.5. Assessment of complex V activity
Complex V activity was measured as oligomycin-
sensitive, Mg2-ATPase activity [26]. Mitochondria
(50 Wg) in respiration bu¡er (0.5 ml) were exposed
to acrolein for 5 min at 37‡C, pelleted by centrifuga-
tion, resuspended in 0.1 ml of 25 mM HEPES (pH
7.4), and frozen at 380‡C. Mitochondria were
thawed on ice and diluted in 0.4 ml 25 mM HEPES
(pH 7.4) containing 5 mM MgCl2 at 37‡C. Mito-
chondria were incubated at 37‡C for 5 min to induce
swelling and breaking, followed by the addition with
2.5 mM ATP for 5 min. The reaction was terminated
by the addition of 1/10 volume of 3 N perchloric acid
(PCA), and the inorganic phosphate (Pi) content was
measured [27]. Background Pi controls were taken to
be the Pi content of samples which were treated with
PCA prior to addition of ATP. Oligomycin (2 Wg/ml)
was added to parallel samples to determine the oli-
gomycin-insensitive rate. These rates were subtracted
from the total rate to determine the oligomycin-sen-
sitive Mg2-ATPase activity.
2.6. Measurement of cytochrome c release
Isolated mitochondria were exposed to acrolein in
respiration bu¡er containing substrates and ATP (3
mM). Incubations were terminated by ¢ltration
through a 0.2 Wm spin ¢lter (Costar). The ¢ltrate
was stored at 380‡C until analyzed. Alamethicin
(4 Wg/ml; Sigma) exposure was used as a positive
control for mitochondrial release of cytochrome c
[28]. Analysis of cytochrome c in the mitochondrial
medium was performed using an HPLC method de-
veloped in our laboratory using a Jupiter 5 micron
C4 reverse phase column (150U4.6 mm; Phenomen-
ex) with pre-column ¢lter on a Waters 2690 HPLC
system with diode array capability (Waters) [29]. Ab-
sorption at 393 nm was used for detection. Cyto-
chrome c isolated from rat heart (Sigma) was used
as a standard.
2.7. Measurements of acrolein and HNE reactivity
with mitochondria
Adduction reactivities of acrolein and HNE were
estimated by measuring the amount of acrolein and
HNE remaining after 5 and 10 min incubations with
mitochondria in the respiratory bu¡er at 37‡C. Mi-
tochondria were heated at 100‡C for 10 min to in-
activate any metabolizing enzymes prior to mixing
with the alkenal. Acrolein content was assayed using
a procedure in which acrolein reacts with m-amino-
phenol in the presence of 1.5 N HCl to form the
£uorescent 7-hydroxyquinoline (350 nm excitation/
500 nm emission) that was quantitated using reverse
phase HPLC [30]. Addition of the m-aminophenol
derivatization solution was used to stop the reaction
of acrolein with the mitochondrial solution. Zero
time points were samples in which the derivatization
reagent was added to the mitochondrial solution pri-
or to addition of acrolein. Samples were centrifuged
through a 0.2 Wm spin ¢lter (Costar) prior to injec-
tion.
HNE content was measured by reverse phase
HPLC analysis using 220 nm detection [31]. Reac-
tions were terminated with the addition of 1/10 vol-
ume of 3 N PCA and acetonitrile (1:1 v/v). The zero
time points were samples in which PCA was added to
the mitochondrial solution prior to addition of HNE.
Samples were centrifuged through a 0.2 Wm spin ¢lter
(Costar) prior to injection. Thiol content of mito-
chondrial samples was determined by incubating
the samples with 5,5P-dithio-bis(2-nitrobenzoic acid)
(DTNB; Sigma) [32].
2.8. Statistical analyses
Statistical comparisons were performed using Stu-
dent’s t-test or two-way analysis of variance (AN-
OVA) where appropriate using Prism software
(GraphPad) Results are expressed as the mean þ
S.E.M.
3. Results and discussion
The ¢rst set of experiments were designed to ana-
lyze the e¡ects of acrolein on the respiratory param-
eters of isolated rat CNS mitochondria. Acrolein
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inhibited ADP-induced state 3 respiration with com-
plex I-linked substrates, IC50 of approx. 0.4 Wmol/mg
protein, and with complex II-linked substrates, IC50
of approx. 0.5 Wmol/mg protein (Fig. 1). State 4 res-
piration was not altered by the concentrations
of acrolein tested. Addition of the uncoupler carbon-
yl cyanide m-chlorophenylhydrazone (m-CCCP;
0.2 WM) restored succinate-linked respiration to the
ADP-induced, control state 3 rate (Fig. 2) and indi-
cated that complex II through complex IV is not a
target of acrolein. These results are similar to the
e¡ects of acrolein upon isolated rat hepatic mito-
chondria [33]. In contrast, acrolein inhibits complex
II-linked state 3 and uncoupled respiration in mito-
chondria isolated from rat heart [34]. Indeed, we and
others have shown that mitochondria isolated from
rat brain, rat heart, or rat liver may have di¡ering
responses to exposure to other K,L unsaturated alde-
hydes such HNE and 4-hydroxyhexenal [35^37].
Under these experimental conditions, m-CCCP did
not stimulate complex I-linked uncoupled respiration
with glutamate and malate as substrates in control
samples. Propionaldehyde, an analogue of acrolein
lacking the C2 double bond, was ine¡ective even at
1.5 Wmol/mg, indicating that acrolein caused respira-
tory inhibition through Michael adduction [33].
Acrolein (0.75 Wmol/mg) did not inhibit NADH:
cytochrome c oxidoreductase activity (complexes
I^III) or oligomycin-sensitive, Mg2-stimulated
ATPase (complex V) activity. In total, the data
from the oxygen consumption measurements, show-
ing no loss of electron transport between complex II
and complex IV, and the individual complex assays
demonstrated that no rate-limiting inhibition of the
respiratory complexes I^V occurred. These ¢ndings
are in contrast to the complex III inhibition caused
by HNE, and indicate that the structure of the alke-
nal in£uences the adduction target [25].
Potential remaining targets of acrolein-mediated
inhibition of state 3 respiration include Pi transport,
substrate transport, the adenine nucleotide translo-
case, or citric acid cycle enzymes. Respiratory im-
pairment by acrolein in hepatic mitochondria occurs
in part by interrupting Pi transport, analogous to the
thiol alkylating agent N-ethylmaleimide and formal-
dehyde [33,38^40]. Attempts to measure Pi-induced
swelling (based on the procedures of Johnson and
Chappell) under the same conditions used in our ex-
periments were not successful [39]. Malate transport
into the mitochondria is dependent on matrix Pi con-
tent and hence would also be decreased with inhibi-
tion of the Pi transporter [39]. In addition, acrolein
inhibits glutamate transport in hepatic mitochondria
[33]. Thus, respiratory inhibition in brain mitochon-
dria by acrolein is likely the result of acrolein adduc-
tion to multiple targets.
Fig. 2. Uncoupled complex II-linked respiration is not inhibited
by acrolein. Mitochondria were incubated with acrolein
(0.75 Wmol/mg) and substrate (succinate plus rotenone) for
5 min prior to the addition (denoted by the arrow) of ADP
(1 mM) or the uncoupler m-CCCP (0.2 WM).
Fig. 1. Acrolein inhibits ADP-induced respiration. Mitochon-
dria were incubated with substrates for 5 min with increasing
doses of acrolein followed by the addition of ADP (1 mM) to
induce state 3 respiration. Glutamate and malate were used as
complex I-linked substrates. Succinate with rotenone was used
as the complex II substrate. Results are the mean þ S.E.M. of
¢ve to eight samples per data point of experiments using mito-
chondria isolated from two di¡erent animals on two separate
days for each substrate. Control complex I-linked state 3 respi-
ration was 166 þ 4 nmol O2/min/mg and 160 þ 4 nmol O2/min/
mg for two separate experiments. Control complex II-linked
respiration was 460 þ 16 nmol O2/min/mg and 338 þ 5 nmol O2/
min/mg for two separate experiments. Two-way ANOVA indi-
cated that the use of substrate in£uenced the e¡ect of acrolein
(P6 0.05).
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Mitochondrial uptake of calcium, particularly fol-
lowing the opening of ionotropic glutamate recep-
tors, can lead to the generation of reactive oxygen
species with ensuing cell death [41,42]. Thus, we de-
termined whether acrolein altered mitochondrial cal-
cium transporter activity by measuring calcium-in-
duced increases in oxygen consumption, an e¡ect
blocked by an inhibitor of the mitochondrial calcium
transporter, ruthenium red (0.2 WM) [41,43]. Calci-
um-induced respiration was not diminished by acro-
lein with succinate as substrate, and only partially
inhibited with glutamate and malate (Fig. 3). Basal
respiratory rates (with substrates and ATP present)
were not altered. These data suggest that the calcium
transporter activity is not compromised by acrolein.
Similar to data in Fig. 1, these data also pointed to
an increased sensitivity of complex I-linked respira-
tion to acrolein exposure.
The release of cytochrome c from the mitochon-
drial intermembrane space is one trigger for apopto-
sis, and is proposed as a major signaling pathway in
neurodegenerative disease [44,45]. This release may
occur independently of respiratory inhibition or of
transition pore opening [28,46]. Acrolein, at a con-
centration that inhibited ADP-induced respiration,
did not induce cytochrome c release (Fig. 4).
Prior work from our laboratory shows that the
thiol scavenger N-acetylcysteine does not prevent
HNE-mediated inhibition of respiration, possibly be-
cause of the hydrophobic nature of HNE versus the
hydrophilicity of the thiol scavengers [25]. In con-
trast, pretreatment of mitochondrial with a 2-fold
excess glutathione, N-acetylcysteine, or the methyl
ester of N-acetylcysteine signi¢cantly attenuated the
e¡ects of acrolein (Fig. 5). These data suggested that
the structure of the toxic alkenal is a factor when
determining the e⁄cacy of thiol-based protectants.
Lastly, we compared the reactivities of acrolein
and HNE with mitochondrial nucleophiles by mea-
suring the loss of alkenal over time when incubated
with heat-inactivated mitochondria (Fig. 6). Acrolein
Fig. 4. Acrolein does not cause cytochrome c release. Mito-
chondria were incubated in respiratory bu¡er containing sub-
strates, ATP (3 mM), and acrolein for 5 min. The incubation
was terminated by ¢ltration to remove mitochondria. The ¢l-
trate was analyzed by HPLC for cytochrome c content. Each
point represents the mean þ S.E.M.; n = 3 from a single prepara-
tion of mitochondria *P6 0. 05 using Student’s t-test.
Fig. 3. Acrolein inhibits calcium-induced respiration but not the
calcium transporter activity. (A) Increase in respiration by calci-
um addition. In trace A, mitochondria were incubated in respi-
ratory bu¡er containing succinate with rotenone and ATP (3
mM). After 5 min (shown by the arrow), the ability of the mi-
tochondria to increase respiration because of uptake of calcium
was tested by the addition of CaCl2 (1 Wmol/mg). In trace B,
the calcium transporter inhibitor ruthenium red (0.2 WM) was
included. In trace C, acrolein (0.75 Wmol/mg) was added. The
ratio of respiratory rates before and after calcium addition was
used to calculate the percent induction by calcium in panel B.
(B) Acrolein inhibits respiration induced by glutamate and ma-
late (shaded squares) but not by succinate with rotenone
(shaded circles). Each point represents the mean þ S.E.M.; n = 3
or 4 from a single preparation of mitochondria. *P6 0. 05 us-
ing Student’s t-test to compare each concentration of acrolein
to the control (0 Wmol/mg acrolein).
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loss was rapid compared to HNE. Indeed, loss of
HNE was negligible at 10 min as compared to the
30% loss of acrolein. The 30% loss of acrolein rep-
resented 0.150 Wmol of acrolein/mg protein; how-
ever, brain mitochondrial preparations contained
only approx. 0.05 Wmol of thiols/mg protein as mea-
sured by incubation with DTNB [32]. These data
indicated that acrolein alkylated mitochondrial nu-
cleophiles other than thiols.
Lipid peroxidation and mitochondrial dysfunction
have been observed in chronic neurodegenerative dis-
ease and acute cerebral insult. Exactly how these two
phenomena interact is not known. In this work, we
studied multiple endpoints of mitochondrial patho-
physiology relevant to neurodegeneration and found
that respiratory function is compromised by acrolein
exposure. The brain has shallow energy reserves such
that increases in energy demand must be met by in-
creases in energy production by the mitochondria
[47]. This environment is complicated by cytosolic
calcium present following ionotropic glutamate re-
ceptor opening [42]. The failure of the mitochondrion
to increase neuronal energy requirements in the face
of increased ADP may lead to neuronal toxicity. Our
data indicated that acrolein did not a¡ect basal levels
of respiration but rather impeded increases in respi-
ration by elevated ADP levels. The fact that acrolein
did not inhibit calcium transporter activity suggests
that calcium-induced free radical generation can still
occur in mitochondria exposed to acrolein [41]. We
hypothesize that the accumulation of alkenal adducts
on the mitochondrion may render the neuron vulner-
able to energy stress under conditions where an in-
crease in mitochondrial respiration is needed.
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